Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist, achieves superior HbA1c reduction (up to 2.6%) and weight loss (up to 15.7%) compared to other GLP-1 RAs and insulin, making it a highly effective treatment for T2D and obesity.
Tirzepatide is a once-weekly injection that targets both GLP-1 and GIP hormones. It is highly effective for lowering blood sugar (up to 2.6% HbA1c reduction) and promoting significant weight loss (up to 15.7%). It is more effective than many other GLP-1 RAs and insulin, making it a top-tier option for managing T2D and obesity, despite being an injection.
Tirzepatide (5, 10 and 15 mg doses) is the first dual GLP-1 and GIP RA approved for T2D and chronic weight management with up to 2.6% mean HbA1c reduction, 15.7% mean weight loss (WL) and good safety and tolerability profile.
Why this rating
Based on multiple Phase 3 SURPASS trials comparing it to other established treatments.
Source
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Prathima Gogineni et al. · Expert Opinion on Pharmacotherapy · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →